MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Aggressive cancers often have activating mutations in growth-controlling oncogenes and inactivating mutations in tumor-suppressor genes. In neuroblastoma, amplification of the MYCN oncogene and inactivation of the ATRX tumor-suppressor gene correlate with high-risk disease and poor prognosis. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeineldin, Maged, Federico, Sara, Chen, Xiang, Fan, Yiping, Xu, Beisi, Stewart, Elizabeth, Zhou, Xin, Jeon, Jongrye, Griffiths, Lyra, Nguyen, Rosa, Norrie, Jackie, Easton, John, Mulder, Heather, Yergeau, Donald, Liu, Yanling, Wu, Jianrong, Van Ryn, Collin, Naranjo, Arlene, Hogarty, Michael D., Kamiński, Marcin M., Valentine, Marc, Pruett-Miller, Shondra M., Pappo, Alberto, Zhang, Jinghui, Clay, Michael R., Bahrami, Armita, Vogel, Peter, Lee, Seungjae, Shelat, Anang, Sarthy, Jay F., Meers, Michael P., George, Rani E., Mardis, Elaine R., Wilson, Richard K., Henikoff, Steven, Downing, James R., Dyer, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021759/
https://www.ncbi.nlm.nih.gov/pubmed/32060267
http://dx.doi.org/10.1038/s41467-020-14682-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021759/
https://www.ncbi.nlm.nih.gov/pubmed/32060267
http://dx.doi.org/10.1038/s41467-020-14682-6

Ejemplares similares